Kerry Group plc ("Kerry") has announced that it has reached agreement to acquire c. 92% of the issued share capital of c-LEcta GmbH (‘c-LEcta‘) for a consideration of €137m, with management to retain the balance. This follows the acquisition of 100% of the issued share capital of Enmex S.A. de C.V. (‘Enmex‘) on 14 December for a consideration of €62m.
c-LEcta is a biotechnology innovation company specializing in precision fermentation, optimized bio-processing, and bio-transformation for the creation of high-value targeted enzymes and ingredients. Based in Leipzig, Germany and employing over 100 people, c-LEcta has established itself as an innovator in disruptive new sciences for the pharmaceutical market, with a strong pipeline of functional bioactives across food, beverage, and other consumer markets.